AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$CORT

MAHONEY DAVID L sold $12.3M of CORT (indirect holdings)

MAHONEY DAVID L sold 103,606 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $118.25 ($117.47–$119.64, $12.25M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHONEY DAVID L
Published Aug 20, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The director's $12.3M sale may trigger short‑term sell pressure but could be neutral if viewed as routine.

02

Market read

Primary insider sale; modest materiality for traders monitoring biotech stocks.

03

What to watch

Sale executed via pre‑arranged 10b5‑1 plan, which may be routine and not reflective of new information.

Relevance 6/10Novelty 7/10Timing: filing on Aug 20, reflects recent Aug 18 sale

Background

SEC Form 4 filing discloses insider transactions; provides transparent view of insider holdings.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Director David L. Mahoney sold 103,606 shares for $12.3M on Aug 18 via a 10b5‑1 plan.

Expected impact

Downward pressure on CORT price in the short term.

Evidence & confidence

Large $12M sale by a key insider suggests potential concerns about future prospects.

Market effects

Sector

May weigh on other small‑cap biotech stocks as insider activity is monitored.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Insider could be diversifying portfolio; sale does not necessarily imply negative fundamentals.

Key entities

  • Company
    Corcept Therapeutics Inc.

    Biopharmaceutical company developing therapies for endocrine disorders.

  • Individual
    David L. Mahoney

    Director of Corcept Therapeutics who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CORT insider trading history →

Related articles

OCT 26
$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

investing.com2 min
OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min